NervGen is restoring life's potential by creating innovative solutions for the treatment of nerve damage.

NervGen is advancing its lead compound, NVG-291, for the treatment of spinal cord injury and multiple sclerosis, two indications that have significant market opportunities, are a high cost burden to the healthcare system and have a dramatic impact on quality of life. As a therapy, NVG-291 has shown remarkable preclinical promise to alleviate or improve the symptoms and conditions associated with spinal cord injury and multiple sclerosis, potentially allowing human patients to live more active and productive lives. There are currently no therapeutics approved for either nerve regeneration or remyelination.

In addition to spinal cord injury and multiple sclerosis, the Company is embarking on a research initiative to advance its proprietary therapeutic technology platform to generate new treatments for Alzheimer's disease, a progressive neurodegenerative disorder that destroys memory and cognitive functions. Alzheimer's disease is becoming a healthcare crisis with an estimated 30 million people affected globally, including 5.8 million in the United States. As Alzheimer's disease research and development efforts have had limited success in producing new effective treatments, the medical community and pharmaceutical industry are seeking technologies with novel approaches through new targets and pathways.

The Company plans to initiate a Phase 1 human clinical trial on healthy subjects in early 2020 and expansion of that trial in the second half of 2020 to include a cohort of spinal cord injury patients. In addition, NervGen has plans to commence a Phase 2 multiple sclerosis clinical trial in early 2021.

NervGen’s platform technology targets protein tyrosine phosphatase sigma ("PTPσ"), a neural receptor that impedes nerve regeneration and remyelination. Inhibition of the PTPσ receptor has been shown to promote regeneration of damaged nerves and improvement of nerve function in animal models for various medical conditions. NervGen’s core technology has also been shown to remyelinate nerves in demyelinated regions, leading to functional improvement.

Our Team

Protein Tyrosine Phosphatase sigma (PTPσ)


PTPσ inhibitors could revolutionize the treatment of spinal cord injury and conditions related to nerve damage by being the first therapeutic to

  • overcome the body's inhibitory mechanism to nerve growth, 

  • promote nerve regeneration, and

  • bring functional benefit to patients with nerve damage.

Latest News and Publications
NervGen Pharma Responds to Recent Increase in Market Activity


NervGen Pharma Appoints Paul Brennan as President & Chief Executive Officer / Lloyd Mackenzie Appointed to the New Position of Chief Operating Officer


NervGen Pharma Completes Share Issuance to Drug Manufacturing Partner CSBio


Corporate Presentations


NervGen Corporate Presentation

© 2019



Website last updated January 31, 2020. The information posted was accurate at the time of posting, but may be superseded by subsequent disclosures.  

This website may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward looking statements in light of new information or future events. You should also review our most recent filings on SEDAR ( for a more complete discussion of these factors and other risks, particularly under the heading “Risk Factors.”